PDCD1 and neoplasm: Esteban-Fabró and colleagues showed that combining anti-PD-1 therapy with Cabozantinib, a small molecule tyrosine kinase inhibitor largely selective for c-Met and VEGFR2, increased anti-tumour efficacy compared with monotherapies [90].